title: Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors.
abstract: A series of 3,4-diaryloxazolones were prepared and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2). Extensive structure-activity relationship work was carried out within this series, and a number of potent and selective COX-2 inhibitors were identified. The replacement of the methyl sulfone group on the 4-phenyl ring by a sulfonamide moiety resulted in compounds with superior in vivo antiinflammatory properties. In the sulfonamide series, the introduction of a methyl group at the 5-position of the oxazolone ring gave rise to very COX-2-selective compounds but with decreased in vivo activity. Selected 3,4-diaryloxazolones exhibited excellent activities in experimental models of arthritis and hyperalgesia. The in vivo activity of these compounds was confirmed with the evaluation of their antipyretic effectiveness and their ability to inhibit migration of proinflammatory cells. As expected from their COX-2 selectivity, most of the active compounds lacked gastrointestinal toxicity in vivo in rats after a 4-day treatment of 100 mg/kg/day. Within this novel series, sulfonamides 9-11 have been selected for further preclinical evaluation.
authors.affiliation: Almirall Prodesfarma S.A., Research Center, Cardener 68-74, 08024 Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Puig
authors.forename: M I
authors.initials: MI
authors.lastname: Crespo
authors.forename: N
authors.initials: N
authors.lastname: Godessart
authors.forename: J
authors.initials: J
authors.lastname: Feixas
authors.forename: J
authors.initials: J
authors.lastname: Ibarzo
authors.forename: J M
authors.initials: JM
authors.lastname: Jiménez
authors.forename: L
authors.initials: L
authors.lastname: Soca
authors.forename: I
authors.initials: I
authors.lastname: Cardelús
authors.forename: A
authors.initials: A
authors.lastname: Heredia
authors.forename: M
authors.initials: M
authors.lastname: Miralpeix
authors.forename: J
authors.initials: J
authors.lastname: Puig
authors.forename: J
authors.initials: J
authors.lastname: Beleta
authors.forename: J M
authors.initials: JM
authors.lastname: Huerta
authors.forename: M
authors.initials: M
authors.lastname: López
authors.forename: V
authors.initials: V
authors.lastname: Segarra
authors.forename: H
authors.initials: H
authors.lastname: Ryder
authors.forename: J M
authors.initials: JM
authors.lastname: Palacios
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D001169:Arthritis, Experimental / Q000188:drug therapy; D016861:Cyclooxygenase Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000627:therapeutic use; D005334:Fever / Q000188:drug therapy; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D010080:Oxazoles / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000627:therapeutic use; D011451:Prostaglandin-Endoperoxide Synthases / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013329:Structure-Activity Relationship
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D010080:Oxazoles; D011451:Prostaglandin-Endoperoxide Synthases